

CBE ID

1857

Title

HER2 negative or undocumented breast cancer patients spared treatment with HER2-targeted therapies

Project

Cancer

Endorsement Status

Endorsement Removed

Is Under Review

No

Previous Endorsement Cycle

Fall 2020

Removal Date

Sun, 11/01/2020 - 19:00

Initial Endorsement

Mon, 10/22/2012 - 07:59

Steward

American Society of Clinical Oncology

1.0 New or Maintenance

Maintenance

1.1 Measure Structure

Single Measure

1.3 Electronic Clinical Quality Measure (eCQM)

No

1.6 Measure Description

Proportion of female patients (aged 18 years and older) with breast cancer who are human epidermal growth factor receptor 2 (HER2)/neu negative who are not administered HER2-targeted therapies

1.7 Measure Type

Process

1.8 Level of Analysis

Clinician: Group/Practice

1.9 Care Setting

Outpatient Services

1.14 Numerator

HER2-targeted therapies not administered during the initial course of treatment.

1.15 Denominator

Adult women with breast cancer that are HER2 negative or HER2 undocumented.

1.20 Types of Data Sources

Registry data

6.1.2 Current or Planned Use(s)

Payment Program, Quality Improvement with Benchmarking (external benchmarking to multiple organizations), Regulatory and Accreditation Programs

6.1.3 Current Use(s)

Payment Program, Quality Improvement with Benchmarking (external benchmarking to multiple organizations), Regulatory and Accreditation Programs

Exclusions

Patient transfer to practice during or after initial course.

Planned Use

Payment Program

Risk Adjustment

No risk adjustment or risk stratification

Steward Organization

American Society of Clinical Oncology

Steward POC email

Tayyaba.Shehzadi@asco.org